Haves-Zburof et al. evaluated whether the expression levels of cathepsins B and S and their inhibitors, cystatins B and C, are affected by the MS disease state and therapies (IFN-β and methylprednisolone) and whether they are associated with the IFN-β response phenotype. This evidence concerns the gene IFNB1 and myeloid sarcoma.